Effect of tadarafil for persistant pulmonary hypertension early after congenital heart surgery in childre
Not Applicable
- Conditions
- congenital heart disease associated with pulmonary hypertension after open heart surgery
- Registration Number
- JPRN-UMIN000013317
- Lead Sponsor
- Osaka Medical College Department of Pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
case who is administered other drugs for pulmonary hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method blood pressure, heart rate, pulmonary artery pressure, SpO2, blood concentration of tadarafil (before administration, 2,4,6,8,12,16,20,24 hours after administration)
- Secondary Outcome Measures
Name Time Method presence or absence of adverse event of tadarafil